Sold-out crowd discusses PCSK9 impact, Hep-C treatment, among other
topics of interest across the industry
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--
A sold-out crowd gathered in New York City from September 1-3, 2015,
where Magellan Rx Management, the pharmacy benefit management division
of Magellan Health, Inc. (NASDAQ: MGLN) recently hosted its 12th annual
Specialty Summit. Discussion focused on developments within the
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) class of drugs,
new Hepatitis C treatments and the associated costs, as well as other
challenges and advancements in the management of specialty drugs. More
than 300 representatives of health plans, employer groups, states, third
party administrators, oncologists and practice managers, consultants,
brokers and pharmaceutical manufacturers participated in the three-day
"At Magellan Rx Management, we believe that the thoughtful debate and
dialogue featured each year at our Specialty Summit drives new,
innovative thinking and helps generate creative solutions to complex
pharmacy challenges," said Mostafa Kamal, chief executive officer of
Magellan Rx Management. "Attendees have come to expect candid and
thought-provoking panelists and presentations that help to advance the
industry as a whole, and we are thrilled to host the right environment
to accomplish just that."
The new PCSK9 inhibitor medications, with a cost exceeding $14,000 per
patient and a target population that could grow substantially, remain a
timely concern to payers. Dr. Jorge Plutzky, director of preventive
cardiology at Brigham and Women's Hospital, and a Harvard Medical School
faculty member, led the discussion about PCSK9 inhibitors at the
"These drugs are a completely novel therapeutic strategy and may be
particularly important in individuals with high cardiovascular disease
risk, including those with familial hypercholesterolemia," Plutzky
said. "Clinical outcomes data expected over the next few years will
further help determine PCSK9 inhibitor use in the statin era."
The management of Hepatitis C was another timely topic discussed at this
year's Specialty Summit. "The new treatment regimens for Hepatitis C
have brought to light the amazing advances that we have made to nearly
eradicate a previously chronic and often debilitating disease," said Dr.
Munish Khaneja, EmblemHealth's vice president of medical management and
pharmacy operations. "The management of specialty drugs has also changed
the way we look at pharmacy costs, elevating the need to not only
include them as part of the total cost of medical care but also find
novel ways to effectively manage and predict these costs."
In addition to the potential impact of the PCSK9 drugs and strategies
for managing Hepatitis C, other topics covered during this year's
Specialty Summit included:
The impact of biosimilars on the pharmaceutical industry and health
Strategies for managing medical benefit drugs.
The emerging cost of orphan drugs.
Magellan Rx Management is a pharmacy benefit manager that specializes in
solving complex pharmacy challenges for its customers. Magellan Rx
Management offers full-service capabilities, including formulary
management, claims processing, specialty pharmacy management, targeted
clinical solutions and home delivery service.
About Magellan Health: Headquartered in Scottsdale, Ariz., Magellan
Health, Inc. is a leader in managing the fastest growing, most
complex areas of health, including special populations, complete
pharmacy benefits and other specialty areas of healthcare. Magellan
develops innovative solutions that combine advanced analytics, agile
technology and clinical excellence to drive better decision making,
positively impact health outcomes and optimize the cost of care for the
members we serve — all within a customer-first culture. Magellan's
customers include health plans and other managed care organizations,
employers, labor unions, various military and governmental agencies,
third party administrators, consultants and brokers. For more
information, visit MagellanHealth.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150911005474/en/
Magellan Health, Inc.
Renie Shapiro Silver, 877-645-6464
Source: Magellan Health, Inc.
News Provided by Acquire Media